Search

Displaying results 1791 - 1800 of 6951 in total

Drug
Baricitinib
go.drugbank.com/drugs/DB11817
ApprovedInvestigational
[A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … the use of baricitinib for the treatment of COVID-19 in May 2022.
Categories: Experimental Unapproved Treatments for COVID-19
Drug
Revefenacin
go.drugbank.com/drugs/DB11855
ApprovedInvestigational
The LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD
Categories: Drugs for Obstructive Airway Diseases
Drug
Lopinavir
go.drugbank.com/drugs/DB01601
ApprovedInvestigational
[A191757] Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.[L12012] … Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
Drug
Amorolfine
go.drugbank.com/drugs/DB09056
ApprovedWithdrawn
It is not approved for the treatment of onychomycosis in the United States or Canada. … It is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries
Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
Drug
Oxtriphylline
go.drugbank.com/drugs/DB01303
Approved
As such, oxytriphylline is indicated mainly for asthma, bronchospasm, and COPD (i.e. all the same indications as the other theophyllines). … Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator.
Categories: Drugs for Obstructive Airway Diseases
Drug
Ibrexafungerp
go.drugbank.com/drugs/DB12471
Approved
Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic Use
Drug
L-Glutamine
go.drugbank.com/drugs/DB00130
ApprovedInvestigationalNutraceutical
It is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Drug
Nitazoxanide
go.drugbank.com/drugs/DB00507
ApprovedInvestigationalVet approved
Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
Drug
Susoctocog alfa
go.drugbank.com/drugs/DB11606
ApprovedInvestigational
Susoctocog alfa serves to temporarily restore the inhibited endogenous Factor VIII for effective hemostasis. … Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection.
Drug
Streptococcus pneumoniae type 18c capsular polysaccharide antigen
go.drugbank.com/drugs/DB10335
ApprovedInvestigational
It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For Injection